Tvardi Therapeutics Statistics
Tvardi Therapeutics (0HTC) Stock Statistics & Valuation Metrics
Total Valuation
Tvardi Therapeutics has a market cap or net worth of $15.74M. The enterprise value is -$6.34M.
- Market Cap
- $15.74M
- Enterprise Value
- -$6.34M
Share Statistics
Tvardi Therapeutics has 13,338,943 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 13,338,943
- Owned by Insiders
- 3.36%
- Owned by Institutions
- 10.53%
Financial Efficiency
Tvardi Therapeutics’s return on equity (ROE) is -0.87 and return on invested capital (ROIC) is -126.49%.
- Return on Equity (ROE)
- -0.87
- Return on Assets (ROA)
- -0.57
- Return on Invested Capital (ROIC)
- -126.49%
- Return on Capital Employed (ROCE)
- -1.27
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.52M
- Employee Count
- 12
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Tvardi Therapeutics is -0.44. Tvardi Therapeutics’s PEG ratio is 0.01.
- PE Ratio
- -0.44
- PS Ratio
- 0.00
- PB Ratio
- 0.97
- Price to FCF
- -0.63
- Price to Operating Cash Flow
- -0.60
- PEG Ratio
- 0.01
Income Statement
In the last 12 months, Tvardi Therapeutics had revenue of 0 and earned -18.21M in profits. Earnings per share was -2.46.
- Revenue
- 0
- Gross Profit
- -95.00K
- Operating Income
- -26.75M
- Pretax Income
- -18.21M
- Net Income
- -18.21M
- EBITDA
- -18.12M
- Earnings Per Share (EPS)
- -2.46
Cash Flow
In the last 12 months, operating cash flow was -25.03M and capital expenditures 0, giving a free cash flow of -25.03M billion.
- Operating Cash Flow
- -25.03M
- Free Cash Flow
- -25.03M
- Free Cash Flow per Share
- -1.98
Dividends & Yields
Tvardi Therapeutics pays an annual dividend of $0.29, resulting in a dividend yield of ―
- Dividend Per Share
- $0.29
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -159.02%
- Earnings Yield
- -178.55%
Stock Price Statistics
- Beta
- -0.62
- 52-Week Price Change
- -78.86%
- 50-Day Moving Average
- 3.38
- 200-Day Moving Average
- 10.38
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
Tvardi Therapeutics upcoming earnings date is Apr 06, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 13, 2026
- Next Earnings Date
- Apr 06, 2027
- Ex-Dividend Date
- Mar 15, 2022
Financial Position
Tvardi Therapeutics as a current ratio of 2.86, with Debt / Equity ratio of 0.96%
- Current Ratio
- 2.86
- Quick Ratio
- 2.86
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.13
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Tvardi Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Tvardi Therapeutics EV to EBITDA ratio is 0.24, with an EV/FCF ratio of 0.26.
- EV to Sales
- 0.00
- EV to EBITDA
- 0.24
- EV to Free Cash Flow
- 0.26
- EV to Operating Cash Flow
- 0.26
Balance Sheet
Tvardi Therapeutics has $15.77M in cash and marketable securities with $145.00K in debt, giving a net cash position of $15.62M billion.
- Cash & Marketable Securities
- $15.77M
- Total Debt
- $145.00K
- Net Cash
- $15.62M
- Net Cash Per Share
- $1.17
- Tangible Book Value Per Share
- $0.86
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Tvardi Therapeutics is $8.17, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $8.17
- Price Target Upside
- 141.62% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 7
- Revenue Growth Forecast
- -100.00%
- EPS Growth Forecast
- 67.96%
